Home > Resources > Whitepapers > Sample Preparation Technologies for Improved Peptide Quantitation Workflow.

Sample Preparation Technologies for Improved Peptide Quantitation Workflow.

New sample preparation technologies can bring considerable benefit in terms of higher sample throughput and data quality to peptide quantitation. When these are combined with advances across the entire workflow, better quality, analysis speed, and greater return on investment are all achievable

Spotlight

HIMSS Analytics

HIMSS Analytics is a global healthcare advisor, providing guidance and market intelligence solutions that move the industry forward with insight to enable better health through the use of information and technology. In utilizing maturity models, HIMSS Analytics identifies best practices and outlines a strategic roadmap that leads transformational change. HIMSS Analytics has helped hospitals and clinical practices track and benchmark their EMR adoption and utilization goals since 2005 through the EMR Adoption Model (EMRAM). EMRAM provides a roadmap and guidance along an 8-stage model with comparisons to healthcare organizations in the same country and around the world.

OTHER WHITEPAPERS

Cell Lysate Sample Handling with Simoa Bead-Based Assays

whitePaper | November 12, 2019

This document describes a novel Quanterix lysate diluent for running lysate samples with Simoa assays diluent.

Innovative strategies to maintain product integrity in Biologic andBiosimilar clinical studies

whitePaper | August 7, 2022

The number of biologic new molecular entities approved by the FDA has increased over the last five years indicates a growing focus on biosimilar.

Valorization of Starch to Biobased Materials

whitePaper | May 30, 2022

Many concerns are being expressed about the biodegradability, biocompatibility, and longterm viability of polymer-based substances. This prompted the quest for an alternative source of material that could be utilized for various purposes.

Enabling the Future of Cell & Gene Therapies through Non Proprietary Patient-Owned Data Collection

whitePaper | March 16, 2021

Cell and gene therapies have emerged as a new treatment paradigm, and with them has come the potential to alter the course of many rare diseases. In many cases, there is an opportunity to correct the underlying dysfunction with a one-time administration of a therapy and provide either a functional cure or a substantial improvement in health outcomes. In other cases, long term symptom relief will be the primary therapeutic objective. Some of these indications may require more than one dose to achieve continued symptom relief and scientists and companies are working on technologies that will enable the use of a repeat dose.

Transforming cell & gene therapy manufacturing

whitePaper | February 25, 2022

Digitalization and automation promise a better way to streamline the transfer of cell and gene therapies from drug discovery – to commercial production.

Early engagement and regulatory considerations for biotech

whitePaper | March 24, 2023

Biotechnology companies are at the epicenter of innovative drug development, with discoveries spanning from small molecules, large molecules, and biologics to genomic medicines and first-inclass immunotherapies.